



Press release

**MEDIAN Technologies announces
a reserved share capital increase to FURUI
of €19.6 Million at a €13 per share price**

This share capital increase reserved to Furui Medical Science Company Luxembourg will allow MEDIAN Technologies to accelerate implementation of its global growth plans and further enhance customer offerings

Sophia Antipolis, France – November 7th, 2016 – MEDIAN Technologies (ALMDT.PA), a leading medical imaging solutions provider, today announces that it has entered into an investment agreement with Furui Medical Science Company Luxembourg, a wholly owned subsidiary of Inner Mongolia Furui Medical Science Co., Ltd. (FURUI), according to which MEDIAN Technologies will issue and Furui Medical Science Company Luxembourg will subscribe, 1,507,692 new ordinary shares of the company at a price of €13.00 per share representing a total amount of €19,599,996 through a reserved share capital increase. This share capital increase will allow MEDIAN Technologies mainly to develop business opportunities for China for the company's products and also for general working capital and other general corporate purposes of the company.

Inner Mongolia Furui Medical Science Co., Ltd. (FURUI) is a leading healthcare group listed on **ChiNext GEM Board (SZ 300049)**, dedicated to pharmaceutical, diagnosis and medical services, with a turnover of around 100M Euros. Furui has abundant medical and market resources that will help Median expand in the Chinese market.

The newly issued ordinary shares will be added to the 10,084,334 MEDIAN Technologies' currently outstanding shares, and will be assimilated to the existing ordinary shares of the company and listed on Alternext, and represent as of today 14.95 % of the share capital of MEDIAN Technologies, reflecting a dilution of 13.01 % for the existing shareholders. Furui Medical Science Company Luxembourg immediately after completion of the transaction will hold 13.01% of the share capital and 13,03% of the voting rights of MEDIAN Technologies.

Furui Medical Science Company Luxembourg's subscription undertaking is subject to the completion of customary conditions precedent for such kind of transaction, particularly obtaining the approval of the resolutions relating to the share capital increase at the shareholders' meeting of MEDIAN Technologies to be held on December, 16th 2016. The transaction enjoys the support of the members of MEDIAN Technologies' Board which has approved unanimously the above mentioned share capital increase on November 4th, 2016, including the founders of the company Mr Brag and Mr Milhiet.



Mr Brag has undertaken, following completion of the transaction, upon request of Furui, to take all necessary steps in order to enable the appointment of Furui Medical Science Company Luxembourg (or a representative designated by it) as a director of the company.

Trading of MEDIAN Technologies shares has been suspended for one (1) day and shall start again on Tuesday, November 8th 2016.

“We are proud to have Furui Medical Science becoming a strategic investor and partner to help MEDIAN grow in China. China is one of the fastest growing healthcare market worldwide and will represent a key area of growth for MEDIAN. The MEDIAN offer aimed at bio-pharmaceutical companies and the patientcare market is very attractive for the Chinese market. This capital increase demonstrates the strong confidence of major Chinese healthcare groups such as Furui Medical Science on MEDIAN’s capability to penetrate the promising Chinese healthcare market with innovative solutions”, said Mr. Fredrik Brag, Chairman and CEO of MEDIAN Technologies.

“MEDIAN plans to collaborate with Furui Medical Science to develop cancer related programs for patient screening, diagnosis and follow-up markets, using both MEDIAN Lesion Management Solutions and MEDIAN iBiopsy™ Platform”, said Mr. Gérard Milhiet, Executive Vice President and co-founder of MEDIAN Technologies.



About MEDIAN Technologies: MEDIAN Technologies develops medical imaging software and services dedicated to oncology clinical trials, cancer screening, and clinical practice. MEDIAN Technologies standardizes and automates the interpretation of medical images in oncology to optimize the diagnosis of cancer patients and the assessment of their response to therapy. MEDIAN serves two primary markets: drug development and patient care.

MEDIAN has a strategic partnership with the world’s largest CRO (Contract Research Organization) to offer integrated imaging services for clinical trials to biopharma sponsors worldwide, and a strategic partnership with Canon to develop new imaging technologies, and to address the patient care market.

Founded in 2002, MEDIAN Technologies is based in Sophia-Antipolis, France, and has a US subsidiary in Boston. MEDIAN has a global reach and actively works with clinical sites located in Asia, Europe, North and South America, and Australia.

MEDIAN has received the label "Innovative company" by the BPI and is listed on Euronext Paris' Alternext market (ISIN: FR0011049824, ticker: ALMDT). The company is eligible for the PEA PME SME equity savings plan setup. For more information on MEDIAN, please visit: www.mediantechologies.com

“We are committed to the improvement of cancer patient outcomes through innovation in medical imaging and quality execution for better screening, diagnosis, and monitoring of patients.”





Disclaimer

This press release is for information purposes only. This capital increase has not given and will not give rise to a prospectus approved by the AMF.

This press release does not constitute and may not be considered as a public offer, a subscription offer or a solicitation of public interest for a public offering of financial securities nor does it constitute an offer to sell or the solicitation of a subscription for, or any offer to buy, any securities in France, the United States or any other jurisdiction. The distribution of this press release in certain countries may constitute a breach of applicable laws and MEDIAN Technologies has not authorized the distribution of this press release in any such country. The securities may not be offered or sold in the United States absent registration of such offer and sale under the U.S. securities act of 1933, as amended or an exemption from such registration

This press release contains certain forward-looking statements concerning MEDIAN Technologies, the capital increase described herein, certain related undertakings and MEDIAN Technologies' business and can be identified by the use of forward looking terminology, including the terms "undertake", "develops", "subject to", "will", or other variations or comparable terminology, or by discussions of strategy, plans, objectives, goals, future events or intentions. Such forward-looking statements are based on assumptions that MEDIAN Technologies considers to be reasonable. However, these forward looking statements are subject to numerous risks including the risks set forth in MEDIAN Technologies' annual report for the year ending 2015 (a copy of which is available on www.medianttechnologies.com) and to the development of economic conditions, financial markets and the markets in which MEDIAN Technologies operates. The occurrence of all or part of such risks could cause actual results, financial conditions, performance or achievements of MEDIAN Technologies to be materially different from such forward-looking statements. MEDIAN Technologies specifically disclaims any obligation or responsibility to update or amend any of the information above except as otherwise required by law.

Contacts

MEDIAN Technologies

Fredrik Brag, CEO

+33 4 92 90 65 82

fredrik.brag@mediantechnologies.com

Press

ALIZE RP

Caroline Carmagnol

Wendy Rigal

+ 33 1 44 54 36 66

median@alizerp.com

Investors

ACTIFIN

Ghislaine Gasparetto

+ 33 1 56 88 11 11

ggasparetto@actifin.fr